bmiMD review
Both products are sold explicitly as microdose lines, which puts them below the doses every trial in this field used.
The verdict
bmiMD's compounded semaglutide card reads $119 a month under a struck $199.80. Its tirzepatide card reads $179 under a struck $299.70. Coverage is 50 states.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- Dose pricing
- Flat across doses
- States
- 50
- From
- From $119/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Availability
- 50 states
bmiMD sells a semaglutide microdose and a dual-agonist microdose by injection, each card showing a monthly rate under a struck-through anchor.
Who writes the prescription, and what do they see?
A prescription precedes dispensing. The pages describe plans and discounts rather than the clinician or the review schedule.
Naming the tier microdose is honest labeling, and it is the fact a reader most needs. No trial has tested a dose below the licensed range, so the evidence behind either molecule does not transfer to what is being sold here.
What happens when the dose goes up?
Microdose is the seller's own framing on both lines, and it locates these products below the trial range rather than at its opening rung. Nothing published says what moving up the ladder costs, or whether it is offered.
What the price includes
A year of the semaglutide line at $119 is $1,428. The tirzepatide line at $179 is $2,148. The struck figures of $199.80 and $299.70 sit above those rates and are not charged.
What it claims, and what it cites
Both lines are compounded and both are microdoses, meaning a smaller quantity of the same molecule rather than a different drug. The FDA does not review a compounded preparation before it is dispensed.
Where it holds up, and where it does not
- Strength: The microdose framing is stated openly
- Strength: Coverage in 50 states
- Strength: Both card rates shown before intake
- Limitation: No trial has tested a dose below the licensed range
- Limitation: Nothing published on dose escalation cost
- Limitation: The strike-throughs are never charged
What the evidence says about this kind of treatment
The assessment above is about bmiMD. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who wants a microdose and understands that is what the low figure buys.
- Wrong for
- A reader expecting the doses the trial results were produced at.
The evidence behind what bmiMD prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How bmiMD compares
| Seller | Who it suits | Go |
|---|---|---|
 Bodi Envi | Patients who value named care partners and can monitor refill notices | See Bodi Envi → |
| Believe Health | Readers who want a low flat rate and know what this storefront actually is | See Believe Health → |
| Big Easy Weight Loss | Readers who can pay a block up front and want the new-patient reduction | See Big Easy Weight Loss → |
More GLP-1 telehealth sellers reviews: Reset SolutionsRestorLife MedRevel HealthRevel RXRevive MedsRewinding RX
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- What is a microdose here?
- A smaller quantity of the same molecule, below the doses the trials used. The seller names both lines that way.
- Are the struck figures charged?
- No. $199.80 and $299.70 sit above the $119 and $179 rates as anchors.
- Is there trial evidence at these doses?
- No trial has tested a dose below the licensed range.
- Is bmiMD legit?
- bmiMD is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
- Is bmiMD expensive compared with other GLP-1 telehealth sellers?
- bmiMD publishes a starting figure of $119/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts bmiMD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.